WOLF SIEGMUND
No ORCID on file
· 30 papers in corpus
· active 2011
Frequent coauthors
- BRUDER SANDRA 30
- OTTO CHRISTIANE 30
- TRAUTWEIN MARK 30
- FREIBERG CHRISTOPH 30
- GREVEN SIMONE 30
- HARRENGA AXEL 30
- EICKER ANDREA 15
- WILMEN ANDREAS 15
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H06, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H08, as well as maturated forms thereof, and antigen-binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 006- H07, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 005- C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or pre…
2011
The present invention is directed to pharmaceutical compositions containing one or more neutralizing prolactin receptor antibodies and antigen binding fragments, and their use in the treatment or prevention of benign disorders and indicatio…
2011
The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indi…